文献速递前列腺癌

激素敏感性与去势抵抗性前列腺癌的基因谱分析及易进展为去势抵抗性前列腺癌的基因突变识别

Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-11-18

本研究共收集103份样本,包括59例激素敏感性前列腺癌(HSPC)患者的62份肿瘤组织DNA及不同癌症阶段前列腺癌患者的41份游离DNA(cfDNA),进行靶向测序。结果显示cfDNA可用于前列腺癌基因谱分析,并建立包含MSH2、CDK12、TP53和RB1四个基因突变的组合可预测转移性HSPC患者早期去势抵抗性前列腺癌(CRPC)进展风险,一致性指数为0.609,ROC曲线下面积为0.838。

要点

  • 1针(80%)和混合12针(77.8%)活检组织DNA测序结果与cfDNA测序高度可比。
  • HSPC患者中最常见突变基因为FOXA1(30.5%)、CDK12(23.7%)和TP53(22.0%)。
  • 50.8%(30/59)和44.1%(26/59)的HSPC患者分别存在DDR和HRR通路突变。

核心结论

  • 本研究表明cfDNA可用于前列腺癌基因谱分析,新建立的组合能够预测哪些mHSPC患者具有早期CRPC进展的高风险。

研究设计与样本

  • 共收集103份样本,包括59例HSPC患者的62份肿瘤组织DNA样本和不同癌症阶段前列腺癌患者的41份cfDNA样本,对组织DNA和cfDNA进行靶向测序,使用χ2检验、逻辑回归分析、Kaplan-Meier分析和Cox回归分析分析突变与临床结局(无CRPC时间)的关联。

主要发现

  • 与cfDNA测序相比,1针(80%)和混合12针(77.8%)活检组织DNA测序结果高度可比。
  • HSPC患者中最常见的突变基因为FOXA1(30.5%)、CDK12(23.7%)和TP53(22.0%)。
  • 50.8%(30/59)和44.1%(26/59)的HSPC患者分别存在DDR和HRR通路突变。
  • CRPC样本中常见AR和APC突变以及参与干细胞多能性调控和EMT通路的成员突变。
  • 建立的四个基因突变组合(MSH2、CDK12、TP53和RB1)预测CRPC早期进展风险的一致性指数为0.609,ROC曲线下面积为0.838。

关键数值与推荐

  • 四个基因突变组合(MSH2、CDK12、TP53和RB1)预测CRPC早期进展风险的一致性指数为0.609,ROC曲线下面积为0.838。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic profiling of patients with prostate cancer could potentially identify mutations prone to castration-resistant prostate cancer (CRPC). Here, we aimed to identify the differences in genetic profiles of patients with hormone-sensitive prostate cancer (HSPC) and CRPC and stratify HSPC patients to identify mutations associated with CRPC progression. METHODS: A total of 103 samples were collected, including 62 DNA samples from the tumor tissues of 59 HSPC patients and 41 cell-free DNA (cfDNA) samples from prostate cancer patients at different cancer stages. Targeted sequence was conducted on both the tissue DNA and cfDNA. The associations between mutations and clinical outcomes (CRPC-free time) were analyzed using χ2 test, logistic regression analysis, Kaplan-Meier analysis, and Cox regression analysis. RESULTS: By comparing to that of cfDNA sequencing, the results from DNA sequencing of 1-needle (80%) and mixed 12-needle (77.8%) biopsies are highly comparable. FOXA1 (30.5%), CDK12 (23.7%), and TP53 (22.0%) were the top 3 most frequently mutated genes in HSPC patients; 50.8% (30/59) and 44.1% (26/59) HSPC patients had mutations in DDR and HRR pathway, respectively. Mutations in AR and APC as well as the members involved in the regulation of stem cell pluripotency and EMT pathway were often observed in CRPC samples. We established a panel of four genetic mutations (MSH2, CDK12, TP53, and RB1) to predict the risk of CRPC early progression with concordance index = 0.609 and the area under curve of the ROC curve as 0.838. CONCLUSIONS: In this study, we demonstrated that the cfDNA can be used in genetic profiling in prostate cancer and our newly established panel is capable of predicting which mHSPC patient has a high risk of early CRPC progression.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Wang Z, Yan X, Tang P, et al. Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 36401126. doi:10.1038/s41391-022-00618-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。